Connection

Co-Authors

This is a "connection" page, showing publications co-authored by HENRY MARK KUERER and KELLY K HUNT.
Connection Strength

12.632
  1. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662.
    View in: PubMed
    Score: 0.598
  2. Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip? Ann Surg Oncol. 2016 10; 23(11):3432-3434.
    View in: PubMed
    Score: 0.556
  3. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
    View in: PubMed
    Score: 0.410
  4. ASO Visual Abstract: Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2024 Nov 19.
    View in: PubMed
    Score: 0.247
  5. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery. 2004 Nov; 136(5):1061-9.
    View in: PubMed
    Score: 0.246
  6. Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Feb; 32(2):922-930.
    View in: PubMed
    Score: 0.246
  7. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. Ann Surg Oncol. 2023 Nov; 30(12):7015-7025.
    View in: PubMed
    Score: 0.225
  8. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Cancer Res. 2003 Feb; 9(2):601-5.
    View in: PubMed
    Score: 0.218
  9. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer. 2002 Dec 01; 95(11):2276-82.
    View in: PubMed
    Score: 0.216
  10. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8.
    View in: PubMed
    Score: 0.201
  11. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
    View in: PubMed
    Score: 0.188
  12. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.
    View in: PubMed
    Score: 0.164
  13. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.157
  14. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.148
  15. Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. Ann Surg Oncol. 2016 08; 23(8):2385-90.
    View in: PubMed
    Score: 0.135
  16. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8.
    View in: PubMed
    Score: 0.134
  17. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9.
    View in: PubMed
    Score: 0.127
  18. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb; 150(2):137-43.
    View in: PubMed
    Score: 0.125
  19. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73.
    View in: PubMed
    Score: 0.119
  20. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
    View in: PubMed
    Score: 0.117
  21. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.113
  22. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9.
    View in: PubMed
    Score: 0.109
  23. Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy. Ann Surg Oncol. 2013 May; 20(5):1514-21.
    View in: PubMed
    Score: 0.108
  24. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13.
    View in: PubMed
    Score: 0.107
  25. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012 Oct; 19(10):3177-84.
    View in: PubMed
    Score: 0.105
  26. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
    View in: PubMed
    Score: 0.104
  27. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20; 30(6):600-7.
    View in: PubMed
    Score: 0.102
  28. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
    View in: PubMed
    Score: 0.100
  29. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg. 2011 May; 127(5):1763-1772.
    View in: PubMed
    Score: 0.097
  30. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011 Oct; 18(10):2873-8.
    View in: PubMed
    Score: 0.096
  31. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
    View in: PubMed
    Score: 0.095
  32. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 2011 Mar 01; 117(5):916-24.
    View in: PubMed
    Score: 0.093
  33. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:343-51.
    View in: PubMed
    Score: 0.093
  34. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47.
    View in: PubMed
    Score: 0.092
  35. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9.
    View in: PubMed
    Score: 0.091
  36. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
    View in: PubMed
    Score: 0.090
  37. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 Oct; 250(4):558-66.
    View in: PubMed
    Score: 0.087
  38. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 01; 115(5):962-71.
    View in: PubMed
    Score: 0.083
  39. A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. Plast Reconstr Surg. 2008 Dec; 122(6):1631-1647.
    View in: PubMed
    Score: 0.082
  40. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77.
    View in: PubMed
    Score: 0.081
  41. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008 Jul 01; 113(1):30-7.
    View in: PubMed
    Score: 0.079
  42. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008 Jul; 196(1):81-7.
    View in: PubMed
    Score: 0.078
  43. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31.
    View in: PubMed
    Score: 0.075
  44. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15; 110(4):723-30.
    View in: PubMed
    Score: 0.075
  45. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007 Apr 01; 109(7):1255-63.
    View in: PubMed
    Score: 0.073
  46. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg. 2006 Oct; 192(4):552-5.
    View in: PubMed
    Score: 0.070
  47. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. 2006 Oct 01; 107(7):1459-66.
    View in: PubMed
    Score: 0.070
  48. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54.
    View in: PubMed
    Score: 0.070
  49. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3):464-70.
    View in: PubMed
    Score: 0.070
  50. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct; 203(4):475-80.
    View in: PubMed
    Score: 0.070
  51. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer. 2006 Aug; 7(3):248-53.
    View in: PubMed
    Score: 0.070
  52. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer. 2006 Mar 16; 6:68.
    View in: PubMed
    Score: 0.068
  53. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
    View in: PubMed
    Score: 0.067
  54. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006 Jan; 243(1):96-101.
    View in: PubMed
    Score: 0.067
  55. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005 Aug 15; 104(4):692-9.
    View in: PubMed
    Score: 0.065
  56. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
    View in: PubMed
    Score: 0.064
  57. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005 Apr; 200(4):516-26.
    View in: PubMed
    Score: 0.063
  58. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer. 2005 Apr 01; 103(7):1323-9.
    View in: PubMed
    Score: 0.063
  59. Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol. 2005 May; 12(5):391-7.
    View in: PubMed
    Score: 0.063
  60. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat. 2005 Jan; 89(2):149-57.
    View in: PubMed
    Score: 0.062
  61. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. Clin Nucl Med. 2005 Jan; 30(1):11-5.
    View in: PubMed
    Score: 0.062
  62. ASO Visual Abstract: Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2025 Jan; 32(1):123-124.
    View in: PubMed
    Score: 0.062
  63. Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2025 Jan; 32(1):84-91.
    View in: PubMed
    Score: 0.061
  64. Sentinel lymph node biopsy following neoadjuvant chemotherapy: review of the literature and recommendations for use in patient management. Asian J Surg. 2004 Oct; 27(4):262-7.
    View in: PubMed
    Score: 0.061
  65. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer. 2004 Oct 01; 101(7):1514-23.
    View in: PubMed
    Score: 0.061
  66. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004 Sep; 11(9):854-60.
    View in: PubMed
    Score: 0.061
  67. Defining Breast Cryoablation Treatment Success: A?Guide for the Curative and Palliative Treatment of Breast Cancer. Acad Radiol. 2024 Dec; 31(12):4759-4771.
    View in: PubMed
    Score: 0.061
  68. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth. 2004 Aug; 16(5):332-41.
    View in: PubMed
    Score: 0.061
  69. Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol. 2024 Oct; 31(11):7264-7270.
    View in: PubMed
    Score: 0.060
  70. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. Cancer. 2004 Jun 15; 100(12):2549-54.
    View in: PubMed
    Score: 0.060
  71. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open. 2024 Jun 03; 7(6):e2418486.
    View in: PubMed
    Score: 0.060
  72. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004 Mar 01; 100(5):942-9.
    View in: PubMed
    Score: 0.059
  73. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer. 2004 Feb 01; 100(3):490-8.
    View in: PubMed
    Score: 0.058
  74. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol. 2004 Feb 01; 22(3):567-8.
    View in: PubMed
    Score: 0.058
  75. Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. Am J Surg. 2004 Feb; 187(2):164-9.
    View in: PubMed
    Score: 0.058
  76. Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol. 2024 Feb; 31(2):974-980.
    View in: PubMed
    Score: 0.058
  77. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 Nov; 10(9):1025-30.
    View in: PubMed
    Score: 0.057
  78. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg. 2003 Oct; 186(4):371-7.
    View in: PubMed
    Score: 0.057
  79. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023 Dec; 30(13):8327-8334.
    View in: PubMed
    Score: 0.057
  80. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34.
    View in: PubMed
    Score: 0.056
  81. Nipple aspirate fluid cytology in breast carcinoma. Cancer. 2003 Apr 25; 99(2):97-104.
    View in: PubMed
    Score: 0.055
  82. Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg. 2003 Mar; 196(3):354-64.
    View in: PubMed
    Score: 0.055
  83. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
    View in: PubMed
    Score: 0.055
  84. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat. 2003 Jan; 77(1):9-14.
    View in: PubMed
    Score: 0.054
  85. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
    View in: PubMed
    Score: 0.054
  86. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002 Sep 01; 95(5):982-8.
    View in: PubMed
    Score: 0.053
  87. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002 Jul; 9(6):543-9.
    View in: PubMed
    Score: 0.052
  88. Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction. Plast Reconstr Surg. 2002 May; 109(6):1888-96.
    View in: PubMed
    Score: 0.052
  89. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res. 2002 May; 22(5):583-92.
    View in: PubMed
    Score: 0.052
  90. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002 Apr; 9(3):228-34.
    View in: PubMed
    Score: 0.051
  91. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002 Apr; 9(3):256-65.
    View in: PubMed
    Score: 0.051
  92. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002 Jan; 194(1):54-64.
    View in: PubMed
    Score: 0.051
  93. Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol. 2001 Dec; 8(10):821-7.
    View in: PubMed
    Score: 0.050
  94. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001 Oct; 182(4):393-8.
    View in: PubMed
    Score: 0.050
  95. Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. J Surg Oncol. 2021 Dec; 124(7):989-994.
    View in: PubMed
    Score: 0.049
  96. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021 Oct; 28(10):5477-5485.
    View in: PubMed
    Score: 0.049
  97. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
    View in: PubMed
    Score: 0.047
  98. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3480-6.
    View in: PubMed
    Score: 0.047
  99. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
    View in: PubMed
    Score: 0.046
  100. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg. 2000 Mar; 190(3):350-63.
    View in: PubMed
    Score: 0.045
  101. Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Ann Surg Oncol. 2020 Mar; 27(3):730-735.
    View in: PubMed
    Score: 0.044
  102. Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. JAMA Surg. 2019 09 01; 154(9):800-809.
    View in: PubMed
    Score: 0.043
  103. Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers. Ann Surg Oncol. 2020 Feb; 27(2):367-372.
    View in: PubMed
    Score: 0.043
  104. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230(1):72-8.
    View in: PubMed
    Score: 0.043
  105. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat. 2019 Jul; 176(2):435-444.
    View in: PubMed
    Score: 0.042
  106. Surgeon perception versus reality: Opioid use after breast cancer surgery. J Surg Oncol. 2019 Jun; 119(7):909-915.
    View in: PubMed
    Score: 0.041
  107. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17(2):460-9.
    View in: PubMed
    Score: 0.041
  108. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 1998 Dec; 5(8):673-80.
    View in: PubMed
    Score: 0.041
  109. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9.
    View in: PubMed
    Score: 0.041
  110. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer. 2019 02 01; 125(3):365-373.
    View in: PubMed
    Score: 0.041
  111. American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Ann Surg Oncol. 2018 Oct; 25(10):2965-2974.
    View in: PubMed
    Score: 0.040
  112. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998 Jul-Aug; 4(4):230-6.
    View in: PubMed
    Score: 0.040
  113. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol. 2018 Oct; 25(10):2932-2938.
    View in: PubMed
    Score: 0.040
  114. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281.
    View in: PubMed
    Score: 0.038
  115. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017 Oct; 24(10):2925-2934.
    View in: PubMed
    Score: 0.037
  116. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34.
    View in: PubMed
    Score: 0.037
  117. Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Acad Radiol. 2017 02; 24(2):191-199.
    View in: PubMed
    Score: 0.036
  118. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659.
    View in: PubMed
    Score: 0.035
  119. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol. 2016 10; 23(10):3190-8.
    View in: PubMed
    Score: 0.035
  120. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol. 2016 10; 23(11):3501-3509.
    View in: PubMed
    Score: 0.034
  121. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
    View in: PubMed
    Score: 0.034
  122. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015 Mar; 261(3):547-52.
    View in: PubMed
    Score: 0.032
  123. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7.
    View in: PubMed
    Score: 0.030
  124. Timing of infectious complications following breast-conserving therapy with catheter-based accelerated partial breast irradiation. Ann Surg Oncol. 2014 Aug; 21(8):2512-6.
    View in: PubMed
    Score: 0.030
  125. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.030
  126. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28.
    View in: PubMed
    Score: 0.029
  127. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61.
    View in: PubMed
    Score: 0.029
  128. Impact of surgical techniques, biomaterials, and patient variables on rate of nipple necrosis after nipple-sparing mastectomy. Plast Reconstr Surg. 2013 Sep; 132(3):330e-338e.
    View in: PubMed
    Score: 0.028
  129. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
    View in: PubMed
    Score: 0.028
  130. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
    View in: PubMed
    Score: 0.028
  131. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol. 2013 Jun; 20(6):1893-9.
    View in: PubMed
    Score: 0.027
  132. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
    View in: PubMed
    Score: 0.026
  133. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
    View in: PubMed
    Score: 0.026
  134. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6.
    View in: PubMed
    Score: 0.025
  135. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012 Jan; 255(1):109-15.
    View in: PubMed
    Score: 0.025
  136. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012 Apr; 19(4):1137-44.
    View in: PubMed
    Score: 0.025
  137. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
    View in: PubMed
    Score: 0.025
  138. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
    View in: PubMed
    Score: 0.025
  139. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24.
    View in: PubMed
    Score: 0.024
  140. A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. Plast Reconstr Surg. 2011 Jun; 127(6):2154-2166.
    View in: PubMed
    Score: 0.024
  141. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011 Apr; 18(4):932-8.
    View in: PubMed
    Score: 0.024
  142. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer. 2010 Nov 01; 116(21):4933-43.
    View in: PubMed
    Score: 0.023
  143. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010 Oct; 17 Suppl 3:280-5.
    View in: PubMed
    Score: 0.023
  144. The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol. 2011 Sep; 79(3):315-20.
    View in: PubMed
    Score: 0.023
  145. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
    View in: PubMed
    Score: 0.023
  146. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010 Dec; 17(12):3252-8.
    View in: PubMed
    Score: 0.023
  147. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer. 2010 Jun 15; 116(12):2878-83.
    View in: PubMed
    Score: 0.023
  148. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8.
    View in: PubMed
    Score: 0.023
  149. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8.
    View in: PubMed
    Score: 0.022
  150. False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden. Breast J. 2009 Nov-Dec; 15(6):645-8.
    View in: PubMed
    Score: 0.022
  151. Improved postoperative pain control using thoracic paravertebral block for breast operations. Breast J. 2009 Sep-Oct; 15(5):483-8.
    View in: PubMed
    Score: 0.021
  152. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg. 2009 Nov; 198(5):720-5.
    View in: PubMed
    Score: 0.021
  153. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg. 2009 Sep; 198(3):387-91.
    View in: PubMed
    Score: 0.021
  154. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer. 2009 Apr 01; 115(7):1555-62.
    View in: PubMed
    Score: 0.021
  155. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol. 2008 May 20; 26(15):2482-8.
    View in: PubMed
    Score: 0.020
  156. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol. 2008 Jun; 15(6):1696-702.
    View in: PubMed
    Score: 0.019
  157. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer. 2007 Dec 01; 110(11):2542-50.
    View in: PubMed
    Score: 0.019
  158. Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg. 2007 Dec; 120(7):1755-1768.
    View in: PubMed
    Score: 0.019
  159. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer. 2007 Aug 15; 110(4):731-7.
    View in: PubMed
    Score: 0.019
  160. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1004-9.
    View in: PubMed
    Score: 0.018
  161. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol. 2007 Apr; 14(4):1458-71.
    View in: PubMed
    Score: 0.018
  162. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 01; 107(7):1440-7.
    View in: PubMed
    Score: 0.018
  163. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg. 2006 Oct; 192(4):541-4.
    View in: PubMed
    Score: 0.018
  164. Impact of sentinel lymph node biopsy on the evolution of breast reconstruction. Plast Reconstr Surg. 2006 Oct; 118(5):1089-1099.
    View in: PubMed
    Score: 0.018
  165. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov; 13(11):1443-9.
    View in: PubMed
    Score: 0.018
  166. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg. 2006 Jul; 203(1):64-72.
    View in: PubMed
    Score: 0.017
  167. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006 May; 93(5):539-46.
    View in: PubMed
    Score: 0.017
  168. The role of ultrasound in the surgical management of patients diagnosed with ductal carcinoma in situ of the breast. Breast J. 2006 May-Jun; 12(3):212-5.
    View in: PubMed
    Score: 0.017
  169. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006 Jun; 13(6):776-82.
    View in: PubMed
    Score: 0.017
  170. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006 Mar; 13(3):310-20.
    View in: PubMed
    Score: 0.017
  171. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64.
    View in: PubMed
    Score: 0.017
  172. Determining the optimal approach to breast reconstruction after partial mastectomy. Plast Reconstr Surg. 2006 Jan; 117(1):1-11; discussion 12-4.
    View in: PubMed
    Score: 0.017
  173. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg. 2005 Oct; 190(4):598-601.
    View in: PubMed
    Score: 0.016
  174. Determinants of mastectomy in breast conservation therapy candidates. Am J Surg. 2005 Oct; 190(4):602-5.
    View in: PubMed
    Score: 0.016
  175. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 01; 104(3):479-90.
    View in: PubMed
    Score: 0.016
  176. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
    View in: PubMed
    Score: 0.016
  177. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7.
    View in: PubMed
    Score: 0.016
  178. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
    View in: PubMed
    Score: 0.016
  179. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004 Dec 01; 22(23):4691-9.
    View in: PubMed
    Score: 0.015
  180. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
    View in: PubMed
    Score: 0.015
  181. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. Cancer. 2004 Oct 25; 102(5):322-7.
    View in: PubMed
    Score: 0.015
  182. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg. 2004 Oct; 199(4):644-51.
    View in: PubMed
    Score: 0.015
  183. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer. 2004 Sep 15; 101(6):1330-7.
    View in: PubMed
    Score: 0.015
  184. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. Cancer. 2004 Aug 01; 101(3):508-17.
    View in: PubMed
    Score: 0.015
  185. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
    View in: PubMed
    Score: 0.015
  186. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
    View in: PubMed
    Score: 0.015
  187. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
    View in: PubMed
    Score: 0.015
  188. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45.
    View in: PubMed
    Score: 0.015
  189. Delayed-immediate breast reconstruction. Plast Reconstr Surg. 2004 May; 113(6):1617-28.
    View in: PubMed
    Score: 0.015
  190. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):128-35.
    View in: PubMed
    Score: 0.014
  191. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003 Apr; 10(3):248-54.
    View in: PubMed
    Score: 0.014
  192. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
    View in: PubMed
    Score: 0.014
  193. Characterization of foam cells in nipple aspirate fluid. Diagn Cytopathol. 2002 Nov; 27(5):261-4; discussion 265.
    View in: PubMed
    Score: 0.013
  194. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol. 2002 Nov; 9(9):912-9.
    View in: PubMed
    Score: 0.013
  195. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg. 2002 Oct; 184(4):364-8.
    View in: PubMed
    Score: 0.013
  196. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
    View in: PubMed
    Score: 0.013
  197. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8.
    View in: PubMed
    Score: 0.013
  198. Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ. 2002 Mar 09; 324(7337):577-81.
    View in: PubMed
    Score: 0.013
  199. Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J. 2002 Mar-Apr; 8(2):177-80.
    View in: PubMed
    Score: 0.013
  200. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002 Jan 01; 20(1):17-23.
    View in: PubMed
    Score: 0.013
  201. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer. 2001 Sep 01; 92(5):1092-100.
    View in: PubMed
    Score: 0.012
  202. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001 Jun; 8(5):425-31.
    View in: PubMed
    Score: 0.012
  203. Educational review: role of the surgeon in hereditary breast cancer. Ann Surg Oncol. 2001 May; 8(4):368-78.
    View in: PubMed
    Score: 0.012
  204. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg. 2001 Apr; 181(4):313-8.
    View in: PubMed
    Score: 0.012
  205. Reduction mammoplasty improves breast conservation therapy in patients with macromastia. Am J Surg. 2001 Mar; 181(3):215-20.
    View in: PubMed
    Score: 0.012
  206. Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg. 2000 Oct; 180(4):252-6.
    View in: PubMed
    Score: 0.012
  207. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol. 2000 Sep; 24(9):1266-72.
    View in: PubMed
    Score: 0.012
  208. Prophylactic mastectomy. J Am Coll Surg. 2000 Sep; 191(3):322-30.
    View in: PubMed
    Score: 0.012
  209. Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer. Breast J. 2000 Jul; 6(4):242-246.
    View in: PubMed
    Score: 0.011
  210. Feasibility of immediate breast reconstruction for locally advanced breast cancer. Ann Surg Oncol. 1999 Oct-Nov; 6(7):671-5.
    View in: PubMed
    Score: 0.011
  211. Special considerations in breast cancer risk and survival. J Surg Oncol. 1999 Aug; 71(4):250-60.
    View in: PubMed
    Score: 0.011
  212. Local recurrence and survival among black women with early-stage breast cancer treated with breast-conservation therapy or mastectomy. Ann Surg Oncol. 1999 Apr-May; 6(3):241-8.
    View in: PubMed
    Score: 0.010
  213. Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol. 1998 Oct-Nov; 5(7):620-6.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.